Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI

Neuroradiology

Volumn 57, Issue 1, 2015, Pages 11-20

  Lescher, Stephanie ^a   Jurcoane, Alina ^a   Veit, Andreas ^a   Bähr, Oliver ^a   Deichmann, Ralf ^b   Hattingen, Elke ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Brain Imaging Center Center for Imaging in Neuroscience   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Bevacizumab; Quantitative MRI; Relaxation times; Tumor progression

Indexed keywords

BEVACIZUMAB; CARMUSTINE; GADOBUTROL; GALUNISERTIB; LOMUSTINE; TEMOZOLOMIDE; TENIPOSIDE; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN MAPPING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG TREATMENT FAILURE; FEMALE; GLIOBLASTOMA; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; QUANTITATIVE T1 MAPPING; QUANTITATIVE T2 MAPPING; THERAPY EFFECT; TUMOR GROWTH; TUMOR RECURRENCE; BRAIN NEOPLASMS; COMPARATIVE STUDY; DISEASE COURSE; MALE; PATHOLOGY; PROCEDURES;

ADULT; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN NEOPLASMS; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES;

EID: 84921936807     PISSN: 00283940     EISSN: 14321920     Source Type: Journal    
DOI: 10.1007/s00234-014-1445-9     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
2. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578
3. Saitta L, Heese O, Förster AF et al (2011) Signal intensity in T2′ magnetic resonance imaging is related to brain glioma grade. Eur Radiol 21(5):1068–1076
4. Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174
5. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729
6. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
7. Stark-Vance V (2005) Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Proceedings of the World Federation of Neuro-Oncology Meeting. Neuro-Oncol 7:369
8. Wagner SA, Desjardins A, Reardon DA et al (2008) Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas [abstract]. J Clin Oncol 26:2021
9. Claes A, Gambarota G, Hamans B et al (2008) Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int J Cancer 22:1981–1986
10. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787
11. Macdonald D, Cascino T, Schold SJ et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280
12. Casanovas O, Hicklin DJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309
13. da Cruz LC H Jr, Rodriguez I, Domingues RC et al (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol 32(11):1978–1985
14. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633–638, Review
15. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972
16. Pope WB, Hessel C (2011) Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials. AJNR Am J Neuroradiol 32(5):794–797
17. Hattingen E, Jurcoane A, Daneshvar K et al (2013) Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neurooncol 15(10):1395–404
18. Rieger J, Bähr O, Muller K et al (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. Neurooncol 99(1):49–56
19. Araki T, Inouye T, Suzuki H et al (1984) Magnetic resonance imaging of brain tumors: measurement of T1. Work in progress. Radiol 150(1):95–98
20. Englund E, Brun A, Larsson EM et al (1986) Tumours of the central nervous system. Proton magnetic resonance relaxation times T1 and T2 and histopathologic correlates. Acta Radiol Diagn 27:653–659
21. Le Bas JF, Leviel JL, Decorps M et al (1984) NMR relaxation times from serial stereotactic biopsies in human brain tumors. J Comput Assist Tomogr 8:1048–1057
22. Ellingson BM, Kim HJ, Woodworth DC et al (2014) Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 271(1):200–210
23. Preibisch C, Deichmann R (2009) T-1 mapping using spoiled FLASH-EPI hybrid sequences and varying flip angles. Magn Reson Imaging 62:240–246
24. Howarth C, Hutton C, Deichmann R (2006) Improvement of the image quality of T1-weighted anatomical brain scans. Neuroimaging 29:930–937
25. Venkatesan R, Lin WL, Haacke EM (1998) Accurate determination of spin-density and T-1 in the presence of RF-field inhomogeneities and flip-angle miscalibration. Magn Reson Med 40:592–602
26. Volz S, Noth U, Rotarska-Jagiela A et al (2010) A fast B1-mapping method for the correction and normalization of magnetization transfer ratio maps at 3T. Neuroimaging 49:3015–3026
27. Hattingen E, Jurcoane A, Bähr O et al (2011) Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neurooncol 13(12):1349–1363
28. Ellingson BM, Cloughesy TF, Lai A et al (2012) Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 106(1):111–119
29. Jenkinson M, Beckmann CF, Behrens TE et al (2012) FSL Neuroimaging 62(2):782–790
30. Jurcoane A, Wagner M, Schmidt C et al (2013) Within-lesion differences in quantitative MRI parameters predict contrast enhancement in multiple sclerosis. J Magn Reson Imaging 38(6):1454–1561
31. Mottershead JP, Schmierer K, Clemence M et al (2003) High field MRI correlates of myelin content and axonal density in multiple sclerosis—a post-mortem study of the spinal cord. J Neurol 250:1293–1301
32. Seewann A, Vrenken H, van der Valk P et al (2009) Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol 66:601–609
33. van Waesberghe JH, Kamphorst W, De Groot CJ et al (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754
34. Chiba Y, Sasayama T, Miyake S et al (2008) Anti-VEGF receptor antagonist (VGA1155) reduces infarction in rat permanent focal brain ischemia. Kobe J Med Sci 54(2):136–146
35. Deoni SC, Peters TM, Rutt BK (2004) Determination of optimal angles for variable nutation proton magnetic spin-lattice, T1, and spin-spin, T2, relaxation times measurement. Magn Reson Med 51:194–199
36. Deichmann R (2006) Fast structural brain imaging using an MDEFT sequence with a FLASH-EPI hybrid readout. Neuroimaging 33:1066–1071
37. Katz D, Taubenberger JK, Cannella B et al (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34:661–669
38. Brück W, Bitsch A, Kolenda H et al (1997) Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42:783–793
39. Oh J, Cha S, Aiken AH et al (2005) Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 21(6):701–708
40. Hoehn-Berlage M, Tolxdorff T, Bockhorst K et al (1992) In vivo NMRT2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn Reson Imaging 10(6):935–947
41. Eis M, Els T, Hoehn-Berlage M (1995) High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 34(6):835–844